{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:49:40Z","timestamp":1761864580707,"version":"3.37.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"French Health Ministery"},{"DOI":"10.13039\/501100008966","name":"Soci\u00e9t\u00e9 Francophone du Diab\u00e8te","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008966","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Novo Nordisk Fondation"},{"name":"Merck-Serono Company"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s40266-023-01067-9","type":"journal-article","created":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T10:02:01Z","timestamp":1697623321000},"page":"1027-1036","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Five-Year Follow-Up of Diabetic Complications and Geriatric Alterations in French Older Patients with Type 2 Diabetes According to Treatment Modalities: The Observational Prospective GERODIAB Cohort"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9892-7490","authenticated-orcid":false,"given":"Jean","family":"Doucet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia","family":"Gu\u00e9rin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Hilbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyse","family":"Bordier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Wils","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"B\u00e9nichou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Bauduceau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,18]]},"reference":[{"key":"1067_CR1","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.diabet.2012.07.001","volume":"38","author":"J Doucet","year":"2012","unstructured":"Doucet J, Le Floch JP, Bauduceau B, Verny C, SFD\/SFGG Intergroup. GERODIAB: glycemic control and 5-year morbidity\/mortality of type 2 diabetic patients aged 70 years and older: description of the population at inclusion. Diabetes Metab. 2012;38:523\u201330.","journal-title":"Diabetes Metab"},{"key":"1067_CR2","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.diabet.2018.05.003","volume":"44","author":"J Doucet","year":"2018","unstructured":"Doucet J, Verny C, Balkau B, Scheen AJ, Bauduceau B. Haemoglobin A1c and 5-year all-cause mortality in French type 2 diabetic patients aged 70 years and older: the GERODIAB observational cohort. Diabetes Metab. 2018;44:465\u201372.","journal-title":"Diabetes Metab"},{"issue":"1","key":"1067_CR3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/fcp.12160","volume":"30","author":"J Doucet","year":"2016","unstructured":"Doucet J, Bauduceau B, Le Floch JP, Verny C, SFD\/SFGG Intergroup. Medical treatments of older, French patients with type 2 diabetes: results at inclusion in the Gerodiab cohort. Fund Clin Pharmacol. 2016;30(1):76\u201381.","journal-title":"Fund Clin Pharmacol."},{"key":"1067_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.demand.2022.100084","author":"J Doucet","year":"2023","unstructured":"Doucet J, Gu\u00e9rin O, Hilbert C, et al. Changes in antidiabetic drug prescription patterns during follow-up of the GERODIAB cohort: comparison with professional recommendations. Diabet Epidemiol Manag. 2023. https:\/\/doi.org\/10.1016\/j.demand.2022.100084.","journal-title":"Diabet Epidemiol Manag."},{"issue":"5","key":"1067_CR5","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s00125-020-05370-7","volume":"64","author":"IC Lega","year":"2021","unstructured":"Lega IC, Campitelli MA, Austin PC, et al. Potential diabetes overtreatment and risk of adverse events among older adults in Ontario: a population-based study. Diabetologia. 2021;64(5):1093\u2013102. https:\/\/doi.org\/10.1007\/s00125-020-05370-7.","journal-title":"Diabetologia"},{"key":"1067_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.571568","volume":"12","author":"K Mattishent","year":"2021","unstructured":"Mattishent K, Loke YK. Meta-analysis: association between hypoglycemia and serious adverse events in older patients treated with glucose-lowering agents. Front Endocrinol (Lausanne). 2021;12: 571568.","journal-title":"Front Endocrinol (Lausanne)."},{"key":"1067_CR7","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2021.1912735","author":"J Scheen","year":"2021","unstructured":"Scheen J. Careful use to minimize adverse events of oral antidiabetic medications in the older. Expert Opin Pharmacother. 2021. https:\/\/doi.org\/10.1080\/14656566.2021.1912735.","journal-title":"Expert Opin Pharmacother"},{"key":"1067_CR8","doi-asserted-by":"publisher","first-page":"304","DOI":"10.2337\/dc13-1540","volume":"37","author":"B Bauduceau","year":"2014","unstructured":"Bauduceau B, Doucet J, le Floch JP, Verny C, SFD\/SFGG Intergroup and the GERODIAB Group. Cardiovascular events and geriatric scale scores in older (70 years-old and above) type 2 diabetic patients at inclusion in the GERODIAB cohort. Diabetes Care. 2014;37:304\u201311.","journal-title":"Diabetes Care"},{"key":"1067_CR9","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, LEADER Trial Investigators, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311\u201322.","journal-title":"N Engl J Med"},{"key":"1067_CR10","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2\u00a0diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9:653\u201362.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1067_CR11","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"1067_CR12","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995\u20132008.","journal-title":"N Engl J Med"},{"key":"1067_CR13","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, EMPEROR-Preserved Trial Investigators, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451\u201361.","journal-title":"N Engl J Med"},{"key":"1067_CR14","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1007\/s00125-005-0023-4","volume":"48","author":"T Cukierman","year":"2005","unstructured":"Cukierman T, Gerstein HC, Williamson JD. Cognitive decline and dementia in diabetes: systematic overview of prospective observational studies. Diabetologia. 2005;48:2460\u20139.","journal-title":"Diabetologia"},{"key":"1067_CR15","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/jdi.12087","volume":"4","author":"K Gudala","year":"2013","unstructured":"Gudala K, Bansal D, Schifano S, Bhansali A. Diabetes mellitus and risk of dementia: a meta-analysis of prospective observational studies. J Diabetes Investig. 2013;4:640\u201350.","journal-title":"J Diabetes Investig."},{"key":"1067_CR16","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.eurger.2014.10.006","volume":"6","author":"C Verny","year":"2015","unstructured":"Verny C, Doucet J, Bauduceau B, et al. Prevalence of cognitive decline and associated factors in older type 2 diabetic patients at inclusion in the GERODIAB cohort. Eur Geriatr Med. 2015;6:36\u201340.","journal-title":"Eur Geriatr Med."}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-023-01067-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-023-01067-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-023-01067-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T10:20:03Z","timestamp":1698229203000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-023-01067-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,18]]},"references-count":16,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["1067"],"URL":"https:\/\/doi.org\/10.1007\/s40266-023-01067-9","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"type":"print","value":"1170-229X"},{"type":"electronic","value":"1179-1969"}],"subject":[],"published":{"date-parts":[[2023,10,18]]},"assertion":[{"value":"31 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors had financial support (unrestricted grants) from the French National PHRC, the Francophone Society for Diabetes, Novo-Nordisk Foundation, and Merck-Serono Company for the submitted work; there were no financial relationships with any organizations that might have had an interest in the submitted work. In the preceding 3 years, there were no other relationships or activities that might have influenced the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jean Doucet, Olivia Gu\u00e9rin, Caroline Hilbert, Lyse Bordier, Julien Wils, Jacques B\u00e9nichou, and Bernard Bauduceau have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interests\/Competing interests"}},{"value":"The study protocol was submitted to the French CCTIRS and CNOM Ethics Committees and was approved on 9 April, 2009 and 7 May, 2009, respectively.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conceptualization: JD, BB; methodology and data collection: JD, CH, OG; formal analysis and investigation: JD, OG, JB; writing, original and reviewed draft preparation: JD; complementary analysis for revision: OG, JW; funding acquisition: JD, BB; supervision: JD.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}